U.S. Veterinary Vaccines Market Size, Share & COVID-19 Impact Analysis, By Product (Inactivated, Live Attenuated, Recombinant, and Others), By Animal (Companion and Livestock), By Route of Administration (Oral, Parenteral, and Others), and By Distribution Channel (Veterinary Hospitals, Veterinary Clinics, Pharmacies & Drug Stores, and Others), and Country Forecast, 2023-2030

The U.S. veterinary vaccines market size was worth USD 4.12 billion in 2022 and is projected to grow at a CAGR of 6.5% during the forecast period. 

The U.S. has witnessed a significant rise in zoonotic disease outbreaks, spurring demand for preventive measures. To tackle these diseases, the U.S. government is actively implementing policies and guidelines to boost companion and livestock animal vaccinations. In March 2022, the U.S. Department of Agriculture (USDA) National Institute of Food and Agriculture (NIFA) invested over USD 13 million in research, funding 17 university projects focusing on novel therapies, prevention strategies, and vaccine development for animal diseases. The goal is to manage and prevent diseases in agriculture animals effectively.

This increased government investment aims to raise awareness about vaccination and reduce the burden of animal diseases. Furthermore, the focus on enhancing and ensuring better accessibility to veterinary care for treating various animal diseases is expected to drive the demand for veterinary vaccines across the country.

The COVID-19 outbreak resulted in slower growth in the U.S. veterinary vaccines market, attributed to a decline in animal visits to veterinary clinical settings for vaccinations compared to the pre-pandemic period.

LATEST TRENDS

Technological Advancements to Increase Vaccine Efficacy Drive Market Growth

The veterinary industry is introducing innovative technologies aimed at enhancing vaccine efficacy, reducing vaccination costs, and identifying and eradicating diseases affecting animals and public health. Animal health companies have long produced various conventional live and inactivated viral vaccines, integral to routine vaccination protocols for companion and livestock animals.

• For instance, the near eradication of the rinderpest virus globally is largely attributed to the critical use of the 'Plowright' vaccine, an attenuated vaccine. While these attenuated viral strains stimulate a natural immune response, they carry risks of residual virulence, reversion to pathogenic wild types, and potential environmental contamination.

The advent of recombinant technology has led to the development of innovative and efficient veterinary vaccines, aiming to improve stability and ease of administration. Third-generation vaccines encompass gene-based platforms such as DNA and RNA, viral vectors, and live or inactivated chimeric vaccines. DNA and RNA-based vaccines represent a novel vaccination approach involving plasmid DNA delivered through injection.

• For example, viral vector vaccines have found application in poultry, food animals, horses, and wildlife. RNA vaccines are being registered for swine use, while DNA vaccines are available for treating melanoma in dogs. Similarly, anti-protozoal vaccines targeting canine leishmaniosis have contributed to reducing disease occurrence in both dogs and humans.

DRIVING FACTORS

Growing Government Investment in Animal Health is Likely to Propel Market Growth

The U.S. government is investing in university projects to support and expedite the introduction of novel preventive measures against crucial zoonotic diseases. Cornell University, for instance, received USD 642,000 from the U.S. Department of Agriculture (USDA) National Institute of Food and Agriculture (NIFA) to develop more effective vaccines for the swine influenza virus, which annually causes significant economic losses in the swine industry.

Furthermore, various regional government agencies have implemented reimbursement plans for producers willing to establish preventive vaccination protocols for their cattle. For instance, the Tennessee Department of Agriculture reimburses USD 7,000 for 30 cattle heads, with a lifetime limit of 3 reimbursements. This program encourages producers to collaborate with Tennessee-licensed large animal veterinarians to develop vaccination protocols for their herds.

Such initiatives have encouraged farmers to proactively manage animal health. Timely vaccination is expected to boost the demand for these vaccines. The increasing animal population and the rising demand for veterinary care have prompted market players to introduce novel and effective products, driving the U.S. veterinary vaccines market growth during the forecast period.

RESTRAINING FACTORS

Growing Distress Over Vaccine Failure May Hamper Market Growth

Despite the increasing adoption of vaccines in animal husbandry, vaccine failures caused by various factors often result in distress among farmers, potentially limiting market growth. The potential threat of disease outbreaks persists even in vaccinated flocks due to these failures. There are numerous causes for vaccine failure, including host factors such as stress, interference with maternally derived antibodies, lack of booster doses, vaccination for immunosuppressed flocks, use of inappropriate dosage, and untimely vaccination schedules.

Several antigen-related factors, such as improper storage, use of expired vaccines, and formulation issues, also contribute to vaccine failure. These failures influence farmers' perceptions of vaccination and may increase resistance to vaccinating their animals. Collectively, these factors hinder the demand for these type of vaccines, thus restraining the U.S. veterinary vaccines market expansion.

According to the American Pet Products Association (APPA) 2021-2022 Survey, 77% of U.S. households own a pet which is equivalent to 90.5 million homes.

SEGMENTATION

By Product Analysis

By product, the market is segmented into inactivated, live attenuated, recombinant, and others.

The live attenuated segment held a dominant U.S. veterinary vaccines market share in 2022. Its growth is attributed to the advantages it offers over other types, such as providing long-lasting immunity with a relatively rapid onset of action. Additionally, the segment's higher growth is facilitated by manufacturers' ability to cost-effectively produce high-quality vaccines.

• For instance, Porcilis Begonia, a product of MSD Animal Health, is a mutant live attenuated vaccine used for the prevention of clinical symptoms and mortality caused by Aujesky's disease. The vaccine provides protective immunization for 4 months.

By Animal Analysis

By animal, the market is bifurcated into companion and livestock.

The livestock segment dominated the U.S. market in 2022. The increasing adoption of vaccination programs for livestock animals contributes to the segment’s growth. Furthermore, factors such as the rising prevalence of animal diseases and increasing expenditure on animal healthcare are driving the segment’s expansion.

• According to the Centers for Disease Control and Prevention 2021 data, it was estimated that more than 6 out of every 10 known infectious diseases spread from animals. Further, it stated that zoonotic diseases are prevalent in the U.S., as 3 out of every 4 are new infections spreading from animals.

By Route of Administration Analysis

Based on route of administration, the market is segmented into oral, parenteral, and others.

The parenteral segment dominated the market in 2022, being one of the most common and traditional routes of administration for veterinary vaccines. It offers benefits such as precise dosing during vaccine delivery and better absorption rates compared to oral or other routes. Furthermore, the anticipated introduction of new products within this segment is expected to further boost its growth.

• In January 2021, Zoetis launched Poulvac Procerta HVT-IBD, a subcutaneous injection, which provides early protection against the contemporary infectious bursal disease (IBD) viruses confronting U.S. broilers.

By Distribution Channel Analysis

Based on distribution channel, the market is segmented into veterinary hospitals, veterinary clinics, pharmacies & drug stores, and others.

The veterinary clinics segment held a dominant share of the veterinary vaccines market in 2022. The increasing number of veterinary clinics and veterinarians nationwide is expected to surge the diagnosis and treatment of animal diseases. Moreover, the increasing number of vaccinations provided in these settings is augmenting the segment’s growth.

• According to the American Veterinary Medical Association 2022 data, there were 124,069 veterinarians, 6.9% higher than veterinarians in 2019 (116,091).

KEY INDUSTRY PLAYERS

In terms of the competitive landscape, a few key players dominate the U.S. veterinary vaccines due to their robust product offerings. Companies such as Elanco, Zoetis, and MSD Animal Health stand out with their strong geographical presence and extensive distribution networks. These companies are further fortifying their market position through strategic decisions. For instance, Elanco signed a distribution agreement with Aptimmune Biologics, Inc., becoming the exclusive distributor of Aptimmune’s porcine reproductive and respiratory syndrome inactivated (or killed) vaccine in the U.S.

Other emerging players such as Virbac, Ceva, and Hester Biosciences Limited are focused on expanding their product portfolios in this market. These companies are investing in expanding their production capacity to meet the escalating demand for veterinary vaccines. For instance, Virbac has established a cutting-edge production unit at its Carros site for pharmaceutical formulation of liquid vaccines and diluents. The objective is to competitively produce large volumes of vaccines and develop new biological products under ongoing research and development.

LIST OF KEY COMPANIES PROFILED:

• Elanco (U.S.)


• HIPRA (Spain)


• Boehringer Ingelheim International GmbH (Germany)


• Virbac (France)


• MSD Animal Health (U.S.)


• Zoetis (U.S)


• Ceva (France)


• NEOGEN CORPORATION (U.S.)


• Hester Biosciences Limited (India)

KEY INDUSTRY DEVELOPMENTS:  

• February 2023 – Mazen Animal Health received patent from the U.S. Patent and Trademark Office (USPTO) for its maize-based vaccines against porcine epidemic diarrhea virus (PEDV).


• September 2022 – MSD Animal Health launched Nobivac Intra-Trac Oral BbPi, the first and only oral vaccine against canine parainfluenza virus in the U.S.


• March 2022 – Ceva launched a sow vaccine to prevent neonatal diarrhea. It is unique as it consists of 7 antigens and has increased its product portfolio.

REPORT COVERAGE

The market report provides a detailed analysis of the industry. It focuses on key aspects such as the prevalence of zoonotic diseases in the U.S. and livestock and companion animal ownership patterns. Additionally, it includes an overview of the regulatory scenario for these vaccines, key industry developments, technological advancements, and the impact of COVID-19 on the market. Besides this, the report offers insights into the market trends and highlights key industry dynamics. In addition to the aforementioned factors, it encompasses several factors that have contributed to the growth of the market over recent years.

Report Scope & Segmentation